Shots:

• Hikma gets exclusive rights to commercialize Yuflyma, the first proposed high concentration, low-volume & citrate-free adalimumab biosimilar in MENA markets
• The agreement will strengthen Hikma’s offering of biosimilar & biologic products with the addition of Yuflyma to its portfolio. Celltrion’s capabilities & well-established commercial presence continue to increase patient's access to vital medications that aid in their battle against challenging diseases
• Hikma has launched three of Celltrion’s biosimilar products i.e., Truxima, Remsima & Herzuma. A fourth product, Remsima SC, an infliximab formulation is currently being developed & will be available soon

Ref: Hikma | Image: Hikma